Charité

Our most important university partner for translational research activities is the Charité - Universitätsmedizin Berlin.

 

Since 2007, the two institutions have jointly run the experimental and clinical research center (ECRC), a center for translational medicine on the Campus Buch. The Max Delbrück Center and the Charité have extended their joint activities even further by forming the Berlin Institute of Health (BIH), which is focusing on translational systems medicine research.

Article

Naked Mole Rats
Institute & Campus

Communicating research in tandem

Two science communications projects of the Max Delbrück Center have received funding from the Stiftung Charité. About 100,000 Euro will go to Gary Lewin and illustrator Kat Menschik for a book on unusual animals in research, and to Russ Hodge and Jennifer von Schlichting for a board game on gene expression.
Porträt
Science

Protecting and repairing neurons

She wants to uncover the mechanisms behind inflammatory neurodegenerative diseases, while also developing new therapeutic approaches and testing them in clinical trials. With these goals in mind, Frederike Cosima Oertel is launching the Translational Neuroimmunology Lab at the ECRC.
Anti-CXCR5 CAR-T cells (green) attack lymphoma cells (magenta) within the stroma cell network of the B cell follicle (light blue).
Press Release No. 18 Berlin

€4.6 million for a novel CAR T-cell therapy

While CAR-T cells have proven successful in treating certain types of leukemia and lymphoma, these immunotherapies can become even more effective. A clinical trial run by Charité and the Max Delbrück Center has been awarded a grant of several million euros to test a new approach.
Scientific image
Press Release No. 16 Berlin

How cancer genes become independent

Sometimes a tumor suddenly starts growing rapidly or becomes resistant to cancerdrugs. This can be caused by a cancer gene “striking out on its own” in ring shapes. ECRC-scientist Anton Henssen described how these DNA rings arise and continue to develop in the journal “Nature Genetics”.
Genomics
Science

Grand finale for European genome project

EASI-Genomics, an EU-funded project designed to facilitate researchers’ access to cutting-edge DNA sequencing technologies, is nearing completion after four years. Janine Altmüller, head of the Genomics Platform, takes stock of what has been accomplished.
Maus
Press Release No. 15 Berlin

Lab animal report for 2022

Studies conducted by research teams at the Max Delbrück Center and its partner institutions used a total of 54,402 animals in 2022. The Center has now submitted these figures to the Berlin State Office for Health and Social Affairs (LaGeSo).
Kathrin de la Rosa
Press Release No. 13 Berlin

Autoantibodies in COVID-19: not always harmful?

Critically ill COVID-19 patients often have antibodies in their blood that bind to the body’s own structures. But these autoantibodies frequently bind to multiple targets, Kathrin de la Rosa’s team reports in “European Journal of Immunology.” This calls into question their role in disease progression.
Wissenschaftlliches Bild
Press Release No. 12 Berlin

Nasal vaccine to prevent COVID-19 passes first tests

Since the beginning of the COVID-19 pandemic, researchers have been working on mucosal vaccines that can be administered through the nose. Now, scientists in Berlin have developed a live attenuated vaccine for the nose. In “Nature Microbiology”, they describe the special immune protection it induces.
Arbeitsgruppenleiter Fabian Coscia prüft die Proben
Science

The key to the right treatment

Berlin-based research project MSTARS is entering its second round. Matthias Selbach and Fabian Coscia explain how the Max Delbrück Center is contributing, why the collaboration with Charité is so important, and how studying proteins in cells can help identify the best therapy for a patient.
Simone Spuler und Verena Schöwel-Wolf
Institute & Campus

Deep expertise, and a bold vision: MyoPax launches in Berlin

MyoPax develops regenerative therapies for previously incurable muscle diseases. An interview with co-founders Prof. Simone Spuler and Dr. Verena Schöwel-Wolf, now board member and CEO respectively